What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “PM577a is being evaluated in participants with Wilson disease caused by biallelic pathogenic, likely pathogenic, or suspected pathogenic ATP7B variants, including at least one p.H1069Q allele.”In the company’s words, NCT07748403 on ClinicalTrials.gov
- Tested for
- Wilson Disease, Wilson's Disease, Wilsons Disease
- Main trialPhase 1/2
- “The purpose of this study is to evaluate the safety, tolerability, biological activity, and initial efficacy of PM577a, an investigational Prime Editing therapy, in adults and adolescents with Wilson disease (WD). Wilson disease is caused by changes (mutations) in the ATP7B gene that prevent the body from removing excess copper normally. PM577a is designed to precisely correct one of the most common disease-causing ATP7B mutations (p.H1069Q) in liver cells with the goal of restoring normal copper metabolism. This is the first study of PM577a in people. Participants will receive a single…”In the company’s words, NCT07748403 on ClinicalTrials.gov
Other drugs for Wilson Disease
Coming up1
- Nov 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Nov 2028 | A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026